Healthcare technology company Medtronic (NYSE: MDT) announced on Wednesday that it has received US Food and Drug Administration clearance for its LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system, expanding the instruments available to US surgeons.
Medtronic said the instrument combines robotic surgery with Medtronic's vessel-sealing technology, which has been used in more than 45 million procedures across more than 65 countries. Designed for use with the Valleylab FT10 energy platform, it seals and cuts vessels, thick tissue and lymphatics up to 7mm in diameter.
The Hugo RAS system is currently cleared for urologic procedures in the US, with Medtronic progressing plans to expand its indications to general and gynecologic surgery. The LigaSure RAS Maryland instrument was introduced on the Hugo system in Europe in 2025 following CE Mark approval.
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
ABL Diagnostics files bid to acquire IntegraGen
ABEC opens new manufacturing facility in Wilson, NC
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026